GW 695634

Drug Profile

GW 695634

Alternative Names: 695634; GW 695634G; GW-5634; GW-695634; GW678248

Latest Information Update: 22 Jun 2006

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiretrovirals
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 31 Dec 2005 Discontinued - Phase-II for HIV-1 infections in USA (PO)
  • 22 Aug 2005 Data presented at the 3rd Conference on HIV Pathogenesis and Treatment have been added to the Viral infections therapeutic trials section
  • 12 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the adverse events , pharmacokinetics and Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top